Mortality, Cardiovascular and Limb Events in Patients With Symptomatic Lower Extremity Artery Disease and Diabetes.


Journal

Angiology
ISSN: 1940-1574
Titre abrégé: Angiology
Pays: United States
ID NLM: 0203706

Informations de publication

Date de publication:
07 2022
Historique:
pubmed: 28 11 2021
medline: 22 6 2022
entrez: 27 11 2021
Statut: ppublish

Résumé

The aim of this study was to compare the prognosis of patients according to diabetes status, during a 1-year follow-up after hospital admission for lower extremity artery disease, in the prospective COPART (COhorte de Patients ARTériopathes) registry. Inclusion criteria were intermittent claudication, ischemic rest pain, tissue loss, or acute limb ischemia, with radiological and hemodynamic confirmation. Among 2494 patients, 1235 (49.5%) had diabetes. Incidence rates for major adverse cardiovascular events (MACE) were 18.0/100 person-years (95% confidence interval [CI], 15.4-21.0) for the diabetes group and 11.1/100 person-years (95% CI, 9.2-13.4) for the non-diabetes group. Incidence rates of all-cause mortality were 29.8/100 person-years (95% CI, 26.5-33.4) for the diabetes group and 19.7/100 person-years (95% CI, 17.2-22.7) for the non-diabetes group. Incidence rates of major limb amputation were 24.2/100 person-years (95% CI, 21.1-27.8) for the diabetes group and 11.6/100 person-years (95% CI, 9.6-14.0) for the non-diabetes group. Diabetes was associated with MACE, adjusted hazard ratio 1.60 (95% CI, 1.16-2.22), and all-cause mortality, unadjusted HR 1.49 (95% CI, 1.24-1.78). In the multivariate analysis, diabetes was no longer associated with major amputation, adjusted HR 1.15 (95% CI, .87-1.51). Patients hospitalized for LEAD with diabetes had a higher risk of MACE than those without diabetes.

Identifiants

pubmed: 34836456
doi: 10.1177/00033197211050144
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

528-538

Commentaires et corrections

Type : CommentIn

Auteurs

François-Xavier Lapébie (FX)

Department of Vascular Medicine, 36760Toulouse University Hospital, Toulouse, France.
UMR 1295 INSERM, CERPOP, 36760Toulouse III, Paul Sabatier University, Toulouse, France.

Vanina Bongard (V)

UMR 1295 INSERM, CERPOP, 36760Toulouse III, Paul Sabatier University, Toulouse, France.
Department of Epidemiology, 36715Toulouse University Hospital, Toulouse, France.
Federation of Cardiology, 36715Toulouse University Hospital, Toulouse, France.

Philippe Lacroix (P)

Department of Cardiovascular and Thoracic Surgery, Vascular Medicine, 36715Limoges University Hospital, Limoges, France.
UMR 1094 INSERM & IRD, 36715Limoges University, Limoges, France.

Victor Aboyans (V)

UMR 1094 INSERM & IRD, 36715Limoges University, Limoges, France.
Department of Cardiology, 36715Limoges University Hospital, Limoges, France.

Joël Constans (J)

Department of Vascular Medicine, 36836Bordeaux University Hospital, Bordeaux, France.
36836Bordeaux University, Bordeaux, France.

Carine Boulon (C)

Department of Vascular Medicine, 36836Bordeaux University Hospital, Bordeaux, France.

Emmanuel Messas (E)

Department of Vascular Medicine, 26930Assistance Publique - Hôpitaux de Paris, Paris, France.
UMR 970 INSERM, 55647Paris Descartes University, Paris, France.

Florence Thomas-Delecourt (F)

AstraZeneca, Courbevoie, France.

David Rosenbaum (D)

AstraZeneca, Courbevoie, France.

Jean Ferrières (J)

UMR 1295 INSERM, CERPOP, 36760Toulouse III, Paul Sabatier University, Toulouse, France.
Department of Epidemiology, 36715Toulouse University Hospital, Toulouse, France.
Federation of Cardiology, 36715Toulouse University Hospital, Toulouse, France.

Alessandra Bura-Rivière (A)

Department of Vascular Medicine, 36760Toulouse University Hospital, Toulouse, France.
UMR 1031 INSERM, StromaLab, Toulouse III, Paul Sabatier University Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH